We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.32 | 0.65% | 49.33 | 49.00 | 49.44 | 49.45 | 48.98 | 49.25 | 1,187,849 | 21:50:39 |
From May 2019 to May 2024
By Colin Kellaher
Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi (SNY) on Sunday said they agreed to restructure their RNAi therapeutics alliance to streamline and optimize development of certain products for the treatment of rare genetic diseases.
As part of the restructuring, Cambridge, Mass., biopharmaceutical company Alnylam will obtain global development and commercialization rights to its investigational RNAi therapeutics programs for the treatment of ATTR amyloidosis, including patisiran and ALN-TTRsc02, while Sanofi obtains global development and commercialization rights to fitusiran, an investigational therapeutic in development for the treatment of hemophilia A and B.
France's Sanofi will receive royalties based on net sales of the ATTR amyloidosis products, and Alnylam will receive royalties based on sales of fitusiran products.
The companies said terms of their 2014 agreement with respect to other products under the alliance are unchanged.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2018 15:44 ET (20:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
